Two-thirds of women with uncomplicated urinary tract infection treated symptomatically with ibuprofen 400 to 600 mg three times a day for three days recovered without use of antibiotics in three separate randomized clinical studies against ciprofloxacin,
mecillinam, and fosfomycin.
With this setup, we could detect the differential growth rate between treatment and reference populations in 3 min for ciprofloxacin, levofloxacin,
mecillinam, nitrofurantoin, and trimethoprim-sulfamethoxazole; 7 min for amoxicillin-clavulanate and doripenem; 9 min for fosfomycin; and 11 min for ampicillin based on 99.
Contemporary resistance trends and mechanisms for the old antibiotics Colistin, temocillin, fosfomycin,
mecillinam and nitrofurantoin.
According to the study conducted by Zhanel G et al, Mean Resistance Rates for 2,000 urinary tract isolates collected from outpatients across Canada in 1998 for ampicillin, trimethoprimsulfamethoxazole,
mecillinam, nitrofurantoin and ciprofloxacin were 41.
All isolates were resistant to cefamandole, ampicillin, cloxacillin, colistin,
mecillinam ciprofloxacin and tetracycline ,while all of isolates were sensitive to Azithromycin ,penicillin G and novobiocin (Table 3).
None of the strains were resistant to
mecillinam or ciprofloxacin.
Mecillinam is a novel [beta]-lactam antibiotic that is active against many members of family Enterobacteriaceae.
Fosfomycin and
mecillinam have been used extensively for the treatment of UTIs, mainly in Scandinavia and Europe, for decades while resistance rates remain low (12).
Enviromental risk assessment of antibiotics: comparison of
mecillinam, trimethoprim and ciprofloxacin.
aureus isolates were found to be resistant to aztreonam, colistin,
mecillinam, metronidazole, polymyxin B and nalidixic acid, but all were found to be sensitive to vancomycin, nitrofurantoin and novobiocin.
Environmental risk assessment of antibiotics: comparison of
mecillinam, trimethoprim and ciprofloxacin.
High, but unchanged, resistance to tetracycline, ampicillin, and chloramphenicol, low resistance to
mecillinam (resistance 3%, intermediate 3%), and to emergence of resistance to azithromycin (resistance 16%, intermediate 62%) and ceftriaxone/cefixime (2%) were detected in 2001-2002.
